Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
263.35M
Enterprise Value
140.91M
Income
-53.31M
Sales
21.57M
Book/sh
1.55
Cash/sh
1.75
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
79
IPO
Sep 25, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
12.21
P/B
2.13
P/C
1.88
P/FCF
-
EV/EBITDA
-
EV/Sales
6.53
Quick Ratio
4.20
Current Ratio
4.20
Debt/Eq
0.14
LT Debt/Eq
0.12
Option/Short
Yes / Yes
EPS (ttm)
-0.65
EPS next Y
-0.46
EPS next Q
-0.14
EPS this Y
58.25%
EPS next Y
15.27%
EPS next 5Y
52.18%
EPS past 3/5Y
19.05% 0.15%
Sales past 3/5Y
- -
EPS Y/Y TTM
59.69%
Sales Y/Y TTM
105.44%
EPS Q/Q
53.03%
Sales Q/Q
-13.12%
Insider Own
43.95%
Insider Trans
0.00%
Inst Own
48.12%
Inst Trans
16.49%
ROA
-39.45%
ROE
-58.36%
ROIC
-38.38%
Gross Margin
93.03%
Oper. Margin
-283.92%
Profit Margin
-247.12%
SMA20
-10.91%
SMA50
-15.03%
SMA200
-19.85%
Trades
Shs Outstand
65.30M
Shs Float
44.73M
52W High
6.83 -51.68%
52W Low
1.29 154.83%
Volatility
6.38% 8.72%
ATR (14)
0.30
RSI (14)
37.09
Beta
1.23
Rel Volume
0.00
Avg Volume
470.70K
Volume
0
Perf Week
-12.70%
Perf Month
-6.52%
Perf Quarter
-49.23%
Perf Half Y
-26.67%
Perf YTD
13.79%
Perf Year
96.43%
Perf 3Y
-8.33%
Perf 5Y
-77.15%
Perf 10Y
-
Prev Close
3.30
Price
3.30
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$8.80
Implied Upside
+166.7%
Analysts9incl. previous ratings
Rating Distribution5 Buy · 1 Hold · 3 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 17, 2026Initiated
JPM logoJJP Morgan
Overweight$12+263.6%
May 04, 2026Initiated
DD. Boral Capital
Buy$9+172.7%
Sep 19, 2024Upgrade
HH.C. Wainwright
Neutral → Buy$5+51.5%
Jun 20, 2024Downgrade
BCS logoBBarclays
Equal Weight → Underweight$3-9.1%
Mar 13, 2024Initiated
JJMP Securities
Mkt Outperform$7+112.1%
Feb 20, 2024Downgrade
HH.C. Wainwright
Buy → Neutral$5+51.5%
Dec 19, 2023Downgrade
MS logoMMorgan Stanley
Equal-Weight → Underweight$10 → $4+21.2%
Nov 21, 2022Downgrade
BAC logoBBofA Securities
Neutral → Underperform$8 → $6+81.8%
Sep 09, 2022Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$19 → $11+233.3%
Jul 29, 2022Initiated
JEF logoJJefferies
Buy$9+172.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bonita David PDirectorApr 21 '26Buy4.442,815,31512,499,99911,808,945Apr 23 06:50 PM
ORBIMED ADVISORS LLCDirectorApr 21 '26Buy4.442,815,31512,499,99911,808,945Apr 23 06:48 PM
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
Ph.D.Dr. Krishna Vaddi D.V.M.
CFOMr. Bryant David Lim J.D.
Chief Scientific OfficerDr. Peggy A. Scherle Ph.D.
Senior VP and Head of Strategic Planning & OperationsMs. Aimee Crombie Ph.D.
Senior Vice President of Technical OperationsDr. Madhu Pudipeddi Ph.D.